AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01602055
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose 500 mg of film coated tablet
Trial: NCT03166527
Drug: Immune Globulin 10% Intravenous Solution
RxNorm normalized name: Immune Globulin 10% Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
Trial: NCT00241982
Drug: long-circulating liposomal prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01080352
Drug: Ascorbic Acid (Vitamin C)
RxNorm normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60grams of ascorbate given intravenous infusion in 1000ml sterile water.
Trial: NCT01292057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match active drug Aripiprazole for 8 days
Trial: NCT04003688
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution (instead of magnesium sulfate, as in the other groups)
Trial: NCT00838162
Drug: TMC310911 75 mg twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
Trial: NCT00838162
Drug: TMC310911 150 mg twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
Trial: NCT00838162
Drug: TMC310911 300 mg twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
Trial: NCT00838162
Drug: TMC310911 300 mg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
Trial: NCT01439438
Drug: Topamax® coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation
Trial: NCT01071876
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule in the morning before breakfast
Trial: NCT01071876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule in the morning before breakfast
Trial: NCT00220844
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01529164
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 iv d1 ,repeat every 14 days
Trial: NCT01993940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally once a day
Trial: NCT01670097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
Trial: NCT02786446
Drug: Naproxen Sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
Trial: NCT03677960
Drug: Topical ABI-1968 cream
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
Trial: NCT02786446
Drug: Lidocaine gel and Naproxen Sodium
RxNorm normalized name: naproxen and diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
Trial: NCT02292979
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2
Trial: NCT00543556
Drug: MK0767
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01500837
Drug: association of RIFAMPIN + CLINDAMYCIN
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: association of RIFAMPIN + CLINDAMYCIN
Trial: NCT01500837
Drug: association of LEVOFLOXACIN+ CLINDAMYCIN
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: association of LEVOFLOXACIN+ CLINDAMYCIN
Trial: NCT01228552
Drug: Topical, intra-oral ketoprofen gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
Trial: NCT01937767
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01211262
Drug: IMCgp100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
Trial: NCT03619330
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
Trial: NCT01779362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching to metformin 1000 mg BI
Trial: NCT01209026
Drug: Placebo Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
Trial: NCT01476904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mcg/inhalation, 2 inhalations QID
Trial: NCT01476904
Drug: Epinephrine inhalation
RxNorm normalized name: EPINEPHrine Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mcg/inhalation, 2 inhalations QID
Trial: NCT04047940
Drug: LY900020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02345850
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Trial: NCT02336308
Drug: Placebo, Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000623
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02070523
Drug: VDCLD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02345850
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
Trial: NCT02121717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take orally
Trial: NCT02129725
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules, 1 capsule po three times a day for 3 months
Trial: NCT02534870
Drug: ABT-450/r/ABT-267
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02534870
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01411774
Drug: Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
Trial: NCT05055687
Drug: FL058
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2500mg、3000mg
Trial: NCT05055687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empty bottle
Trial: NCT05055687
Drug: FL058
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg、1000mg、2000mg
Trial: NCT02670551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01962298
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00575601
Drug: SIMVASTATIN
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
Trial: NCT03718039
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
Trial: NCT00538863
Drug: Fentanyl sublingual spray
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
Trial: NCT01037231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01598896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule by mouth twice daily
Trial: NCT02741024
Drug: Artemether-Lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
Trial: NCT00851500
Drug: K-604
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-604 is given for 26 weeks
Trial: NCT01806272
Drug: Compound Vitamin B12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
Trial: NCT00016653
Drug: Creatine Monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03099720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo fluid will be given at the site of operation locally
Trial: NCT04588324
Drug: SHR2150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive escalating doses of SHR-2150 (starting dose 2 mg) in 3-week treatment cycles.
Trial: NCT04588324
Drug: Anti-Cancer Agent
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The previously resistant first-line cytotoxic regimens, anti-PD-1 antibody and/or anti-CD47 antibody will be administered intravenously Q3W.
Trial: NCT04588324
Drug: SHR2150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive SHR-2150 at RP2D in 3-week treatment cycles.
Trial: NCT02030535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04443725
Drug: Standard of care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
Trial: NCT04647955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated for 8 weeks.
Trial: NCT03280251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
Trial: NCT00107263
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00983021
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, simultaneous dose of placebo, injected s.c. (under the skin)
Trial: NCT01014117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Trial: NCT01014117
Drug: SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
Trial: NCT01120665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
Trial: NCT00565331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline solution
Trial: NCT01029795
Drug: LY2599506
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
Trial: NCT01976806
Drug: Placebo (for Docosahexaenoic acid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
Trial: NCT03370510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray.
Trial: NCT01029795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
Trial: NCT00613249
Drug: HEC-based Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravaginal gel, dosed daily
Trial: NCT02177305
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03578822
Drug: rhPro-UK simulation agent
RxNorm normalized name: Vital E- Repro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
Trial: NCT04483596
Drug: melatonin effect on the Abbreviated Mental Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1
Trial: NCT03573336
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intake orally, once daily
Trial: NCT03070782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% NaCl)
Trial: NCT01525628
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP1A2 probe drug
Trial: NCT00239005
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01750827
Drug: SB659032
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT03045198
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03097692
Drug: Pharmacologic preconditionig
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic preconditionig will be attained by sevoflurane anesthesia
Trial: NCT00080795
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00530166
Drug: sham comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3(100 mg) tablets once daily for 12 weeks
Trial: NCT01709903
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
Trial: NCT01709903
Drug: Placebo to QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QVA149 with SDDPI
Trial: NCT04872231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses.
Trial: NCT01464489
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
Trial: NCT04093596
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy for lymphodepletion
Trial: NCT04092595
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg oral tablet
Trial: NCT04511845
Drug: SPYK04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPYK04 capsule
Trial: NCT04731324
Drug: ZYIL1 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NLRP3 inflammasome inhibitor
Trial: NCT00522041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
Trial: NCT00212433
Drug: Tagitol V, Lo So, Readi-Cat 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00620542
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capsule, oral, once daily
Trial: NCT01282268
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally disintegrating tablet
Trial: NCT03723759
Drug: Faster Aspart 200 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
Trial: NCT03723759
Drug: Faster aspart 100 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
Trial: NCT00288704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
Trial: NCT03224572
Drug: high-dose vitamin C 30gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
Trial: NCT02385760
Drug: CTX-4430
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02385760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00678145
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
Trial: NCT03388463
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg single daily dose.
Trial: NCT00544167
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00544167
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes